Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
J&J calls time on Addex partnership a year after epilepsy fail
Nine months after J&J stepped back from an Addex-partnered epilepsy drug in the wake of a phase 2 fail, the pharma has now severed the relationship.
James Waldron
Apr 17, 2025 7:05am
J&J estimates $400M impact from tariffs, largely in medtech
Apr 15, 2025 2:00pm
J&J reports first cases with Ottava surgical robot
Apr 14, 2025 11:44am
J&J innovator vaults to Valo—Chutes & Ladders
Apr 11, 2025 8:30am
J&J links FcRn blocker to sustained benefits as FDA ruling nears
Apr 8, 2025 10:21am
German program matches lost NIH grants with pharma funders
Apr 7, 2025 10:50am